We are live on ! Find out more
VPC

Vestal Point Capital Portfolio holdings

AUM $3.58B
1-Year Est. Return 189.12%
This Fund
S&P 500
This Quarter Est. Return
+8%
1 Year Est. Return
+189.12%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$1.32B
AUM Growth
-$22.5M
Cap. Flow
-$89.9M
Cap. Flow %
-6.81%
Top 10 Hldgs %
48.68%
Holding
85
New
25
Increased
22
Reduced
17
Closed
16

Top Buys

Rank Stock Value
1
INSM icon
Insmed
INSM
+$62.7M
2
NARI
Inari Medical, Inc. Common Stock
NARI
+$57.6M
3
AGIO icon
Agios Pharmaceuticals
AGIO
+$34.5M
4
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$33.4M
5
GPCR icon
Structure Therapeutics
GPCR
+$22.8M

Top Sells

Rank Stock Value
1
ASND icon
Ascendis Pharma A/S
ASND
+$67.5M
2
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$65.7M
3
GMED icon
Globus Medical
GMED
+$61.6M
4
RARE icon
Ultragenyx Pharmaceutical
RARE
+$53.5M
5
ONC
BeOne Medicines Ltd
ONC
+$49.9M

Sector Composition

Rank Sector Weight
1 Healthcare 96.12%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PASG icon
51
Passage Bio
PASG
$14.1M
$4.27M 0.32%
305,000
+2,400
+0.8% +$38.2K
ALLO icon
52
Allogene Therapeutics
ALLO
$694M
$4.2M 0.32%
1,500,000
-700,000
-32% -$1.87M
PRME icon
53
Prime Medicine
PRME
$556M
$4.14M 0.31%
1,070,000
+620,000
+138% +$2.87M
VTYX
54
DELISTED
Ventyx Biosciences
VTYX
$3.76M 0.29%
1,725,000
+410,000
+31% +$943K
ZVRA icon
55
Zevra Therapeutics
ZVRA
$687M
$3.64M 0.28%
+525,000
New +$3.56M
ARDX icon
56
Ardelyx
ARDX
$988M
$3.44M 0.26%
+500,000
New +$2.95M
PTCT icon
57
PTC Therapeutics
PTCT
$6.12B
$2.97M 0.23%
80,000
-10,000
-11% -$335K
PEN icon
58
Penumbra
PEN
$12.8B
$2.91M 0.22%
+15,000
New +$2.83M
VYGR icon
59
Voyager Therapeutics
VYGR
$198M
$2.87M 0.22%
490,000
-110,000
-18% -$800K
MGNX icon
60
MacroGenics
MGNX
$256M
$2.73M 0.21%
830,000
+30,000
+4% +$117K
VERV
61
DELISTED
Verve Therapeutics
VERV
$2.54M 0.19%
525,000
+25,000
+5% +$145K
ITCI
62
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$2.2M 0.17%
+30,000
New +$2.25M
ESTA icon
63
Establishment Labs
ESTA
$2.27B
$1.73M 0.13%
+40,000
New +$1.74M
RLMD icon
64
Relmada Therapeutics
RLMD
$520M
$1.59M 0.12%
490,000
-710,000
-59% -$2.3M
ACHL
65
DELISTED
Achilles Therapeutics
ACHL
$1.53M 0.12%
1,500,000
– –
OKUR
66
OnKure Therapeutics
OKUR
$167M
$1.36M 0.1%
79,940
+25,440
+47% +$376K
CMRX
67
DELISTED
Chimerix, Inc.
CMRX
$1.3M 0.1%
1,400,000
– –
ATRA icon
68
Atara Biotherapeutics
ATRA
$75.8M
$1.01M 0.08%
124,677
+12,677
+11% +$109K
TENX icon
69
Tenax Therapeutics
TENX
$503M
$288K 0.02%
+83,333
New +$302K
ALXO icon
70
ALX Oncology
ALXO
$280M
– –
-3,600,000
Closed -$21.7M
APLS
71
DELISTED
Apellis Pharmaceuticals
APLS
– –
-335,000
Closed -$12.9M
AXSM icon
72
Axsome Therapeutics
AXSM
$10.9B
– –
-300,000
Closed -$24.1M
BNTX icon
73
BioNTech
BNTX
$23.5B
– –
-100,000
Closed -$8.04M
DNLI icon
74
Denali Therapeutics
DNLI
$3.94B
– –
-500,000
Closed -$11.6M
DYN icon
75
Dyne Therapeutics
DYN
$4.91B
– –
-225,000
Closed -$7.94M
1 2
3
4

Similar funds

WWA
WCG Wealth Advisors Las Vegas, Nevada $3.57B AUM 18.63% 1-Year Est. Return
BPS
BNDES Participacoes SA Rio De Janeiro, Brazil $3.58B AUM
U
Uber San Francisco, California $3.6B AUM 19.81% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
AAP
Arax Advisory Partners Denver, Colorado $3.54B AUM 19.14% 1-Year Est. Return
SCM
Saba Capital Management New York $3.62B AUM 12.96% 1-Year Est. Return
ACM
Advent Capital Management New York $3.63B AUM 0.29% 1-Year Est. Return
TYCC
Texas Yale Capital Corp St. Petersburg, Florida $3.52B AUM 52.63% 1-Year Est. Return

Vestal Point Capital's Q3 2024 Portfolio in Review

As of Q3 2024, Vestal Point Capital held 85 positions worth $1.32B, down 1.7% from $1.34B the previous quarter. Its ten largest holdings account for 49% of the portfolio.

Vestal Point Capital withdrew a net $89.9M in Q3 2024, closing 16 positions and reducing 17 holdings. Its most notable exit was Globus Medical, an estimated $61.6M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, down from 100% a quarter earlier.

Against the trend, Vestal Point Capital opened a new position in Agios Pharmaceuticals worth $33.8M.

  • Vestal Point Capital's largest Q3 2024 buy was Agios Pharmaceuticals: 760,000 shares worth $33.8M.
  • Vestal Point Capital added most to Insmed in Q3 2024, an estimated $62.7M increase.
  • Vestal Point Capital's biggest Q3 2024 reduction was Ascendis Pharma A/S, cutting an estimated $67.5M.
  • Vestal Point Capital fully exited Globus Medical in Q3 2024, selling an estimated $61.6M.
  • Vestal Point Capital's ten largest holdings make up 49% of its $1.32B portfolio in Q3 2024.
  • Vestal Point Capital opened 25 new positions and closed 16 in Q3 2024.
  • Vestal Point Capital's portfolio value fell 1.7% quarter-over-quarter to $1.32B.

Based on Vestal Point Capital's 13F filing for Q3 2024, filed 14 Nov 2024.